ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Adenocarcinoma
Cancer
Carcinoma
Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Lung Cancer
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Paris, Île-de-France, FRA:

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)

with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...

Active, not recruiting
Pancreatic Cancer Non-resectable
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Phase 3

FibroGen
FibroGen

Paris, France and 89 other locations

SOT102 administered as monotherapy (Part C) and in combination with first-line SoC treatment (Part D) in patients with advanced or metastatic pancreatic...

Enrolling
Pancreatic Cancer
Drug: SOT102

Phase 1, Phase 2

SOTIO
SOTIO

Paris, France and 7 other locations

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer...

Active, not recruiting
Chemotherapy-induced Thrombocytopenia
Other: Placebo
Biological: Romiplostim

Phase 3

Amgen
Amgen

Paris, France and 116 other locations

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic du...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Paris, France and 15 other locations

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall surviv...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Drug: nab-paclitaxel
Drug: gemcitabine

Phase 2

Astellas
Astellas

Villejuif, Villejuif Cedex, France and 137 other locations

This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumor...

Enrolling
Exocrine Pancreatic Cancer
Carcinoma, Non-Small-Cell Lung
Drug: cisplatin
Drug: carboplatin

Phase 2

Seagen
Seagen

Villejuif Cedex, Other, France and 63 other locations

given to participants. Part C will use the information from Parts A and B to see if SGN-BB228 is safe and if it works to treat solid tumor cancers...

Enrolling
Non-small Cell Lung Cancer
Pancreatic Neoplasms
Drug: SGN-BB228

Phase 1

Seagen
Seagen

Villejuif Cedex, Other, France and 18 other locations

Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple so...

Enrolling
Bladder Cancer
Non Small Cell Lung Cancer
Drug: Association atezolizumab + BDB001 + RT
Drug: Association atezolizumab + BDB001+ RT

Phase 2

Institut Bergonié

Paris, France and 10 other locations

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immun...

Enrolling
Pancreatic Cancer Harboring NRG1 Fusion
NSCLC Harboring NRG1 Fusion
Drug: zenocutuzumab (MCLA-128)

Phase 2

Merus

Paris, France and 64 other locations

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given...

Active, not recruiting
BRAF Mutant Colorectal Cancer
Lung Squamous Cell Cancer
Biological: PDR001
Drug: LGK974

Phase 1

Novartis
Novartis

Villejuif, France and 19 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems